Jeffrey G. Carr, M.D., F.A.C.C.

Address
115 West Fifth Street
Tyler, TX 75701

Telephone: (903) 595-2283
Fax: (903) 597-2238

Cardiology Practice

• 1994 - Present: Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Education

Academic Degrees

• 1979 - 1983: University of California, Los Angeles, Bachelor of Science - Psychobiology
• 1984 - 1988: University of California, Los Angeles, School of Medicine - Doctor of Medicine

Post Graduate Training

Residency and Internship

• 1988 - 1991: Internal Medicine, UCLA Medical Center

Cardiology Fellowships

• 1991 - 1994: Cardiology Fellowship, UCLA Medical Center
• 1993 - 1994: Interventional Cardiology Fellowship, UCLA Medical Center

Board Certification

• 1991: Diplomate, American Board of Internal Medicine
• 1995: Diplomate, American Board of Internal Medicine - Cardiovascular Disease
• 2000: Diplomate, American Board of Internal Medicine - Interventional Cardiology

Medical Licensure

• State of Texas
• State of California

Hospital Appointments

• 1994 - Present: Acting Staff - Trinity Mother Frances Hospital, Tyler, Texas
• 1994 - Present: Acting Staff - East Texas Medical Center Hospital, Tyler, Texas
• 1994 - Present: Consulting - East Texas Medical Center Hospital, Quitman, Texas
• 1994 - Present: Consulting - East Texas Medical Center Hospital, Crockett, Texas
• 1994 - Present: Consulting - East Texas Medical Center Hospital, Mount Vernon, Texas
• 1994 - Present: Consulting - East Texas Medical Center Hospital, Pittsburg, Texas
• 1994 - Present: Consulting - East Texas Medical Center Hospital, Athens, Texas
• 1997 - Present: Consulting - East Texas Medical Center Hospital, Jacksonville, Texas
• 1997 - Present: Consulting - Laird Memorial Hospital, Kilgore, Texas

Professional Societies, Activities and Other Memberships

• 2003 - Present: Medical Executive Committee- Trinity Mother Frances Hospital, Tyler, Texas
• 1996 - Present: Fellow, American College of Cardiology
• 1997 - Present: Director - Heart Care Partnership - East Texas Medical Center
• 1997 - 2001: Director of Research - East Texas Medical Center Cardiovascular Institute
• 1997 - 1998: President - American Heart Association - Smith County
• 1996 - Present: Lipid Clinic Director - Cardiovascular Associates of East Texas
• 1996 - Present: Director of Clinical Services - Cardiovascular Associates of East Texas
• 1999 - 2000 Credentials Committee - East Texas Medical Center
• 1994 - Present: American Heart Association - Smith County - Board of Directors
• 1994 - Present: American College of Cardiology
• 1994 - Present: American Medical Association
• 1994 - Present: Texas Medical Association
• Past: Smith County Medical Society
• Past: California Medical Society
• Past: American College of Physicians
• Past: Christian Medical Society
• Past: American Society of Echocardiography
• 1993 UCLA Medical Center - Managed Care Committee
• 1989 - 1994 UCLA Coronary Care and Cardiac Observation Unit Committees
• Arteriosclerosis and Thrombosis - Manuscript Reviewer
• American Journal of Cardiology - Manuscript Reviewer

Publications

• Carr JG, Stevenson LW, Walden J, Heber D: Prevalence and hemodynamic correlations of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
  American J. Cardiology 1989; 63; 709-713
• Carr JG, Johnson JA, Kobashigawa JA, Sack JB, Yeatman LA: Does the vasodilator response to nitroglycerin over time affect quantitative assessment of coronary artery lesion dimensions using intravascular ultrasound? J. of the American College of Cardiology 1994; SI:243A
• Carr JG, Miller L, Anderson TF, Murali S, Ventura H, Gordon J, Wilensky R, Yeung AC: Does steroid-free immunosuppression influence the degree of intimal thickening after heart transplantation? A multicenter Study, Circulation, 1994;90:638A
• Kobashigawa JA, Gleeson MP, Stevenson LW, Carr JG, Moriguchi JD, Kawata N, Hamilton MA, Hage A, Drinkwater D, Laks H: Prevention of severe cardiac allograft rejection with Pravastatin: A randomized trial. Journal of the American College of Cardiology 1994;SI:483A
• Johnson JA, Kobashigawa JA, Yeatman L, Carr JG, Trosian KD, Sabad A, Wener LS, Drinkwater D, Laks H: Does pre-existing donor heart atherosclerosis lead to more transplant coronary artery disease? A prospective study using morphometric analysis of intracoronary ultrasound. Journal of American College of cardiology, 1996;2:144A
• Johnson JA, Kobashigawa JA, Yeatman L, Carr JG, Trosian KD, Sabad A, Wener LS, Drinkwater D, Laks H. The distribution and characteristics of transplant coronary disease in a prospective morphometric analysis of intracoronary ultrasound. Journal of American College of Cardiology, 1996:27A

Research

• Principal Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST-segment elevation.
• Principal Investigator - REPLACE II - A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)
• Principal Investigator - REPLACE - TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
• Principal Investigator - Otsuka Protocol 21-98-214-01 CASTLE " A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease."
• Principal Investigator - GUSTO IV ACS - A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of ReoProT, Given as a Bolus Followed by a 24- or 48-Hour Infusion, for the Treatment of Acute coronary Syndrome Without ST-Segment Elevation.
• Principal Investigator - Left Main IVUS Registry - Scripps Clinic - A multicenter prospective registry designed to determine the value of diagnostic IVUS in the setting of an inconclusive coronary angiogram.
• Principal Investigator - PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation -2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.
• Principal Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.
• Principal Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.
• Principal Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.
• Principal Investigator - Intravascular Ultrasound Core Imaging Laboratory (Syntax MUCS1864 TCAD) Randomized, double-blind comparative study of Mycophenolate Mofetil or Azathioprine each in combination with Cyclosporine and corticosteroids for the prevention of rejection in cardiac allograft recipients.
• Co-Investigator - A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
• Co-Investigator - AMIHOT - TherOx Aqueous Oxygen System - Acute Myocardial Infarction with Hyperoxemic Therapy "AMIHOT" Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
• Co-Investigator - SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS). Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532
• Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglepPhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.
• Co-Investigator - A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone ® I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US
• Co-Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparision of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
• Co-Investigator - CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers
• Co-Investigator - ER TIMI 19 - A Phase IV Open-Label Trial of Prehospital Administration of Retavase â for ST elevation MI - the Early Retavase â (ER)-TIMI 19 Trial.
• Co-Investigator - STEP AMI - An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.
• Co-Investigator - MICCAT ( MICardis Community Access Trial) An Phase IV - Open label evaluation of the effectivness of Micardis â ( telmisartan) on blood pressure control and quality of life in patients with essential hypertension.
• Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Co-Investigator - VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Co-Investigator - EPHESUS - IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.
• Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A phase III, randomized, open-label trial evaluating the efficacy and safety of ReoPro TM (ABCIXIMAB) in combination with reduced dose Retavase TM / Rapilysin TM (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
• Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo-controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non Q wave myocardial infarction.
• Co-Investigator - PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion TPA to placebo in acute MI patients with rescue angioplasty.
• Co-Investigator - Coumadin, Aspirin and Reinfarction Study; "CARS" Dup 647-003-459. A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
• Co-Investigator - CARS (Coumadin, Aspirin and Reinfarction Study) EKG Substudy Dup647-003-459. A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
• Co-Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.
• Co-Investigator - TMR012-A. A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with the Eclipse Holmium Laser as an Adjunct to Percutaneous Coronary Intervention
• Co-Investigator - IMDUR (Isosorbide Mononitrate) Patient Acceptability Program. A study comparing the efficacy, safety and ease of use of three FDA-approved formulations; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use.
• Clinical Investigator - Multicenter trial prospectively evaluating the natural history of transplant coronary artery disease (TCAD) assessed by intravascular ultrasound (IVUS).
• Randomized trial on the effects of lipid lowering with Pravastatin on cardiac transplant rejection and TCAD assessed by IVUS.
• Co-Investigator - (NRMI) National Registry for Myocardial Infarction.
• Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System

Honors/Awards

Internal Medicine Honors

• Phi Beta Kappa
• Magna Cum Laude
• Blue Key National Honor Fraternity
• 1991 - 1992: UCLA Medical Center's Outstanding Teacher (Fellow)
• 1991 - 1992: UCLA (Nurses') Physician of the Year

Professional Qualifications/Certifications

• Coronary and peripheral vascular diagnostic angiography and percutaneous interventions
• Vascular Brachytherapy - Beta - Gamma
• Aortic Endograft placement - ANCURE
• Stent Placement - Coronary and Peripheral
• Distal Embolization protection -
  • Filter Wire (BSCI)
  • Percusurge (Medtronic)
• Atherectomy- Coronary and peripheral
  • Laser Atherectomy- Excimer
  • Rotablator -Percutaneous Transluminal Coronary Rotational Atherectomy
  • Coronary and Peripheral
  • Transluminal Extraction Catheter
  • Directional Coronary Atherectomy
  • Intravascular Ultrasound (IVUS) - Coronary and Peripheral
  • Translesional Pressure wire measurement
  • Angiojet Thrombectomy
• Transesophageal Echocardiography
• Stress ECHO

C. Noah Israel, M.D., F.A.C.C.

Address
115 W. Fifth Street
Tyler, TX 75701

Telephone: (903) 595-2283
Fax: (903) 597-2238

Private Practice

• 1982-Present: Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Education

Academic Degrees

• 1968-1972: York College of the City University of New York BA: Biology
• 1972-1976: University Autonoma of Guadalajara Doctor of Medicine

Post-Doctoral Training

• 1976-1977: Fifth Pathway-Rotating Clinical Clerkship, Nassau County Medical Center, Stony Brook, New York
• 1977-1980: Internal Medicine Residency, Danbury Hospital, Danbury, Connecticut

Cardiology Fellowship

• 1980-1982: Baystate Medical Center, Sprinfield, Massachusett

Licensure and Certification

• November 1999: Diplomate Certification Board for Nuclear Cardiology
• October 1995: Nuclear Radiation Certification State of Texas
• November 1983: Diplomate American Board of Cardiovascular Disease
• August 1982: Texas State Board of Medical Examiners
• September 1981: Diplomate American Board of Internal Medicine
  April 1980: State of Massachusetts
• February 1979: State of Connecticut Department of Health
• September 1977: The University of the State of New York

Hospital Appointments

• 1982-Present: Staff - Trinity Mother Frances Hospital, Tyler, Texas
• 1982-Present: Staff - East Texas Medical Center-Tyler, Tyler, Texas
• 1991-Present: Consultant - East Texas Medical Center - Quitman, Texas
• 1983-1997: Consultant - Trinity Memorial Hospital, Trinity, Texas
• 1990-Present: Consultant - East Texas Medical Center - Crockett, Texas
• 1993-Present: Consultant - East Texas Medical Center - Athens, Texas
• 1994-Present: Consultant - East Texas Medical Center - Pittsburg, Texas
• 1994-Present: Consultant - East Texas Medical Center - Mt. Vernon, Texas
• 1997-Present: Consultant - Laird Memorial Hospital, Kilgore, Texas
• 1997-Present: Consultant - East Texas Medical Center - Jacksonville, Texas
• 2000-Present: Consultant - East Texas Medical Center - Carthage, Texas

• 1996-2003: Medical Director Cardiovascular Services East Texas Medical Center, Tyler, Texas
• 1983-1996: Director of Cardiovascular Rehabilitation Trinity Mother Frances Hospital, Tyler, Texas
• 1998-2003: Director of Cardiovascular Rehabilitation East Texas Medical Center, Tyler, Texas
• 1986-1988: Chairman Cardio Pulmonary Section East Texas Medical Center, Tyler, Texas
• 1989-Present: Adhoc Cardiovascular Task Force Committee East Texas Medical Center, Tyler, Texas

Professional Societies and Other Memberships

• Fellow American College of Cardiology
• Fellow American Society of Cardiovascular Interventionists
• Society of Cardiac Angiography and Interventions
• State Board Member, American Heart Association, Texas Affiliate
• Smith County Medical Society
• Texas Medical Association
• American Medical Association
• Diplomate American Heart Association, Council on Clinical Cardiology
• American Heart Association, Smith County Chapter, Past President
• Diplomate American Society of Echocardiography
• Texas Medical Foundation
• Texas Society of Internal Medicine
• American Society of Internal Medicine
• Society of Nuclear Medicine

Research

• Primary Investigator - A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.
• Primary Investigator - GUSTO-Pilot Trial - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries.
• Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries.
• Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; angiography substudy.
• Primary Investigator - GUSTO - TX05 - University of Michigan: Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; two year follow up substudy.
• Primary Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of ReoProT (ABCIXIMAB) in combination with reduced dose RetavaseT/Rapilysin T (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
• Principal Investigator - ER-TIMI 19 - A Phase IV, Open-Label Trial of Prehospital Administration of Retavase® for ST elevation MI - the Early Retavase® (ER) - TIMI 19 Trial
• Primary Investigator - MK-383 Protocol #008-00; A randomized, double-blind study of MK-383 in patients with unstable angina pectoris concomitantly receiving Heparin Collaborative Clinical Researach, Inc.
• Primary Investigator - PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion TPA to placebo in acute MI patients with rescue angioplasty.
• Primary Investigator - IMDUR (isosorbide mononitrate) P94-070 Phase IV Patient Acceptability Program. A study comparing the efficacy, safety and ease of use of three FDA-approved formulation; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit - in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use.
• Principal Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparision of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
• Principal Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Principal Investigator - EPHESUS - IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.
• Investigator - MASTER-- M icrovolt T Wave A lternan S TE sting for R isk S tratification of Post MI Patients.
• Investigator - AWARE - Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias.
• Investigator - FiB07 - A randomized, double-blind study comparing the patency rate and safety of two different preparations of Intravenous Eminase (BRL 26921) in patients with acute myocardial infarction.
• Investigator - The rapid administration of alteplase (rt-Pa) myocardial infarction (RAAMi) Trial: Increased efficiency of 100 mg of rt-PA with modified dosing.
• Investigator - A multi-center, prospective, randomized, placebo-controlled trial of Activase and Heparin in patients with unstable angina (UNSA)
• Investigator - An Anglo-Scandinavian North American multi-center trial of Alteplase (rt-PA) therapy in patients who present with acute myocardial infarction six to twenty-four hours following onset of symptoms. (LATE)- Late Assessment of Thrombolytic Efficacy.
• Investigator - ISIS-3 - The third international study of infarct survival.
• Investigator - Timi-IIIB - Thrombolysis in myocardial ischemia and unstable angina study. Study of the effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction.
• Co-Investigator - Extra Point. Protocol #S1710202. Cardiovascular
• Safety Study of Nicotine Transdermal System.
• Co-Investigator - ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome withour ST- segment elevation.
• Co-Investigator - TMR012-A. A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with the Eclipse Holmium Laser as an Adjunct to Percutaneous Coronary Intervention.
• Co-Investigator - Coumadin, Aspirin and Reinfarction Study; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
• Co-Investigator - Coumadin, Aspirin and Reinfarction EKG Substudy; "CARS" DuP 647-003 A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
• Co-Investigator - NRMI - National Registry for Myocardial Infarction.
• Co-Investigator - PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation - 2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.
• Co-Investigator - BioSlide Catheter SCIMED
• Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo-controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non-Q wave myocardial infarction.
• Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.
• Co-Investigator - VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Co-Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.
• Co-Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.
• Co-Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.
• Co-Investigator - DESTINI (Doppler Endpoint Stenting International Investigation): A multicenter randomized prospective evaluation of clinical outcome comparing primary stenting and a new practice pattern of optimal balloon angioplasty guided by quantitative angiography and intracoronary Doppler.
• Co-Investigator - MICCAT ( MICardis Community Access Trial) An Phase IV - Open label evaluation of the effectivness of Micardis â ( telmisartan) on blood pressure control and quality of life in patients with essential hypertension.
• Co-Investigator - GUSTO IV ACS - A phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ReoProT, given as a bolus followed by a 24- or 48-hour infusion, for the treatment of acute coronary syndrome without ST-segment elevation.
• Co-Investigator - STEP AMI - An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.
• Co-Investigator - REPLACE - TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
• Co-Investigator - REPLACE II - A Randomized Evaluation in PCI Linking
• Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)
• Co-Investigator - SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS).
• Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532
• Co-Investigator - A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone Ò I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US
• Co-Investigator - CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers
• Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglepPhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.
• Co-Investigator - Otsuka Protocol 21-98-214-01 CASTLE " A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease".
• Co-Investigator - AMIHOT - TherOx Aqueous Oxygen System - Acute Myocardial Infarction with Hyperoxemic Therapy "AMIHOT" Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
• Co-Investigator - A Multicenter, Randomized, Double-blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
• Co-Investigator - Extra Point. Protocol #S1710202. Cardiovascular
• Safety Study of Nicotine Transdermal System

Publications

• Jonathan S. Reiner, Conor F. Lundergan, Noah Israel, George Pilcher, Steven Rohrbeck, Mark Thompson, Allan M. Ross for the GUSTO -1 investigators George Washington Univ., Wash., DC: Ventriculographic Evolution in MI Patients with Early Timi 2 Flow; Improving Flow Results in Improving Left Ventricular Function.
  Circulation Vol 92 No 8 Oct 15, 1995 (ABSTRACT)
• Jonathan S. Reiner, MD; Conor F. Lundergan, MD; Anthony Fung, MD; Karin Coyne, R.N. MPH; Shyuan Cho, MS; Noah Israel, MD; John Kazmierski, MD; George Pilcher, MD; James Smith, MD; Steven Rohrbeck, MD; Mark Thompson, MD; Frans Van de Werf, MD; Allan M. Ross, MD; for the Gusto-1 Angiographic Investigators. Evolution of Early TIMI 2 Flow After Thrombolysis for Acute Myocardial Infarction.
  Circulation Vol 94, No 10 Nov. 15, 1996